{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:09:31Z","timestamp":1773702571352,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Barcelona Respitatory Network (BRN)- Fundaci\u00f3 Ramon Pla i Armengol"},{"name":"\u201cClinical project\u201d grant, Fundaci\u00f3 Acad\u00e8mia Ci\u00e8ncies M\u00e8diques de Catalunya i de Balears"},{"name":"\u201cTalents\u201d grant 2020, Fundaci\u00f3 La Pedrera and Hospital Universitari Germans Trias i Pujol."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>NLST and NELSON trial showed that lung cancer mortality can be reduced by 20\u201324% using low-dose computed tomography screening, due to an increase in early-stage diagnoses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Research question<\/jats:title>\n            <jats:p>How much lung cancer-related direct costs may be reduced using low-dose computed tomography screening based on the ILST-protocol in a public healthcare system?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Cost analysis of lung cancer screening vs. usual care in the framework of the retail price of the Catalan public healthcare system. The lung cancer screening group included costs of screening (ILST-protocol), treatment cost according to weighted average distribution of TNM staging in the NLST and NELSON trials, lung cancer detection rate and smoking-cessation intervention. The usual care group included treatment costs based on distribution of TNM staging registered in the Spanish index hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the usual care group, treatment costs were \u20ac91,959. In 5-year of lung cancer screening program, the average expected costs per subject were \u20ac1,342 (range \u20ac1,054\u2009\u2212\u20091,832) for screening and \u20ac32,431 for treatment, with an expected reduction of \u20ac952 based on an average cancer detection rate of 1.6%. The decrease in cost resulting from the stage shift offsets 70.6% of the costs of the screening program.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The decrease in direct costs associated with lung cancer treatment due to a stage shift resulting from LCS of high-risk populations compensates for a substantial part of the LCS program costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Retrospectively registered.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12913-025-13008-w","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:05:15Z","timestamp":1753869915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A cost minimization analysis of the implementation of the international lung screening trial in Catalonia (Spain)"],"prefix":"10.1186","volume":"25","author":[{"given":"Antoni","family":"Rosell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Baeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Mouri\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Saig\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Munn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"L\u00f3pez de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bechini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriol","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Ara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ricou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"L\u00f3pez-Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"3","key":"13008_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"13008_CR2","unstructured":"Asociaci\u00f3n Espa\u00f1ola contra el C\u00e1ncer (AEEC). Impacto del C\u00e1ncer en Catalu\u00f1a 2020. AEEC website. Accessed February 26. 2022. https:\/\/observatorio.contraelcancer.es\/sites\/default\/files\/informes\/cataluna\/Catalu%C3%B1a.pdf."},{"issue":"8","key":"13008_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-Small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623\u201340. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"13008_CR4","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML. Cancer progress and priorities: lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563\u201379. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0221.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"13008_CR5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/JTO.0000000000000559","volume":"10","author":"R Rami-Porta","year":"2015","unstructured":"Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC lung Cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung Cancer. J Thorac Oncol. 2015;10(7):990\u20131003. https:\/\/doi.org\/10.1097\/JTO.0000000000000559.","journal-title":"J Thorac Oncol"},{"issue":"9173","key":"13008_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(99)06093-6","volume":"354","author":"CI Henschke","year":"1999","unstructured":"Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung Cancer action project: overall design and findings from baseline screening. Lancet. 1999;354(9173):99\u2013105. https:\/\/doi.org\/10.1016\/S0140-6736(99)06093-6.","journal-title":"Lancet"},{"issue":"5","key":"13008_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395\u2013409. https:\/\/doi.org\/10.1056\/NEJMoa1102873.","journal-title":"N Engl J Med"},{"issue":"6","key":"13008_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","volume":"382","author":"HJ De Koning","year":"2020","unstructured":"De Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1911793.","journal-title":"N Engl J Med"},{"key":"13008_CR9","doi-asserted-by":"publisher","unstructured":"Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, Sozzi G, Corrao G, Marchian\u00f2 A. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30(7):1162\u201369. https:\/\/doi.org\/10.1093\/annonc\/mdz169, https:\/\/doi.org\/10.1093\/annonc\/mdz117.","DOI":"10.1093\/annonc\/mdz169"},{"key":"13008_CR10","unstructured":"European Parliament. Report on strengthening Europe in the fight against cancer\u2013 towards a comprehensive and coordinated strategy (2020\/2267(INI)). Accessed July 20. 2022. https:\/\/www.europarl.europa.eu\/doceo\/document\/A-9-2022-0001_EN.pdf."},{"key":"13008_CR11","unstructured":"European Parliament. Proposal for a Council Recommendation on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003\/878\/EC. Accessed November 09. 2022. https:\/\/eur-lex.europa.eu\/procedure\/EN\/2022_290."},{"issue":"1","key":"13008_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/RTI.0000000000000367","volume":"34","author":"D Han","year":"2019","unstructured":"Han D, Heuvelmans MA, Vliegenthart R, Rook M, Dorrius MD, Oudkerk M. An update on the European lung Cancer screening trials and comparison of lung Cancer screening recommendations in Europe. J Thorac Imaging. 2019;34(1):65\u201371. https:\/\/doi.org\/10.1097\/RTI.0000000000000367.","journal-title":"J Thorac Imaging"},{"issue":"28","key":"13008_CR13","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year overall survival for patients with advanced Non\u2013Small-Cell lung Cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518\u201327. https:\/\/doi.org\/10.1200\/JCO.19.00934.","journal-title":"J Clin Oncol"},{"issue":"2","key":"13008_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated advanced Non-Small-Cell lung Cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"13008_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2022.05.005","volume":"170","author":"H Grover","year":"2022","unstructured":"Grover H, King W, Bhattarai N, Moloney E, Sharp L, Fuller L. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography. Lung Cancer. 2022;170:20\u201333. https:\/\/doi.org\/10.1016\/j.lungcan.2022.05.005.","journal-title":"Lung Cancer"},{"issue":"69","key":"13008_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22690","volume":"22","author":"T Snowsill","year":"2018","unstructured":"Snowsill T, Yang H, Griffin E, et al. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. Health Technol Assess. 2018;22(69):1\u2013276. https:\/\/doi.org\/10.3310\/hta22690.","journal-title":"Health Technol Assess"},{"issue":"4","key":"13008_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40258-016-0226-5","volume":"14","author":"AJN Raymakers","year":"2016","unstructured":"Raymakers AJN, Mayo J, Lam S, FitzGerald JM, Whitehurst DGT, Lynd LD. Cost-Effectiveness analyses of lung Cancer screening strategies using Low-Dose computed tomography: a systematic review. Appl Health Econ Health Policy. 2016;14(4):409\u201318. https:\/\/doi.org\/10.1007\/s40258-016-0226-5.","journal-title":"Appl Health Econ Health Policy"},{"key":"13008_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2022.02.009","volume":"166","author":"PJ Ngo","year":"2022","unstructured":"Ngo PJ, Cressman S, Behar-Harpaz S, Karikios DJ, Canfell K, Weber MF. Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods. Lung Cancer. 2022;166:122\u201331. https:\/\/doi.org\/10.1016\/j.lungcan.2022.02.009.","journal-title":"Lung Cancer"},{"issue":"8","key":"13008_CR19","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jtho.2017.04.021","volume":"12","author":"S Cressman","year":"2017","unstructured":"Cressman S, Peacock SJ, Tammem\u00e4gi MC, et al. The Cost-Effectiveness of High-Risk lung Cancer screening and drivers of program efficiency. J Thorac Oncol. 2017;12(8):1210\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2017.04.021.","journal-title":"J Thorac Oncol"},{"key":"13008_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.lungcan.2021.06.027","volume":"159","author":"M Diaz","year":"2021","unstructured":"Diaz M, Garcia M, Vidal C, et al. Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis. Lung Cancer. 2021;159:153\u201361. https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.027.","journal-title":"Lung Cancer"},{"issue":"6","key":"13008_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CEJ.0000000000000566","volume":"29","author":"R Guzman","year":"2020","unstructured":"Guzman R, Guirao \u00c0, Vela E, et al. Outcomes and cost of lung cancer patients treated surgically or medically in catalunya: cost-benefit implications for lung cancer screening programs. Eur J Cancer Prev. 2020;29(6):486\u201392. https:\/\/doi.org\/10.1097\/CEJ.0000000000000566.","journal-title":"Eur J Cancer Prev"},{"issue":"3","key":"13008_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/CEJ.0000000000000700","volume":"31","author":"N G\u00f3mez-Carballo","year":"2022","unstructured":"G\u00f3mez-Carballo N, Fern\u00e1ndez-Sober\u00f3n S, Rejas-Guti\u00e9rrez J. Cost-effectiveness analysis of a lung cancer screening programme in Spain. Eur J Cancer Prev. 2022;31(3):235\u201344. https:\/\/doi.org\/10.1097\/CEJ.0000000000000700.","journal-title":"Eur J Cancer Prev"},{"issue":"4","key":"13008_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1513\/AnnalsATS.201902-102OC","volume":"17","author":"KP Lim","year":"2020","unstructured":"Lim KP, Marshall H, Tammem\u00e4gi M, et al. Protocol and rationale for the international lung screening trial. Ann Am Thorac Soc. 2020;17(4):503\u201312. https:\/\/doi.org\/10.1513\/AnnalsATS.201902-102OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"13008_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12094-018-1978-1","volume":"21","author":"M Majem","year":"2019","unstructured":"Majem M, Juan O, Insa A, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol. 2019;21(1):3\u201317. https:\/\/doi.org\/10.1007\/s12094-018-1978-1.","journal-title":"Clin Transl Oncol"},{"key":"13008_CR25","unstructured":"ORDER SLT\/71\/. 2020, of 2 June, Which Regulates the Billable Cases and Concepts and Approves the Public Prices Corresponding to the Services Provided by the Catalan Institute of Health. Accessed December 29, 2021. http:\/\/cido.diba.cat\/legislacio\/10263520\/ordre-slt712020-de-2-de-juny-per-la-qual-es-regulen-els-suposits-i-conceptes-facturables-i-saproven-els-preus-publics-corresponents-als-serveis-que-presta-linstitut-catala-de-la-salut-departament-de-salut."},{"key":"13008_CR26","doi-asserted-by":"publisher","first-page":"S913","DOI":"10.1016\/j.jtho.2021.08.158","volume":"16","author":"R Myers","year":"2021","unstructured":"Myers R, Mayo J, Atkar-Khattra S, et al. MA10.01 prospective evaluation of the international lung screening trial (ILST) protocol for management of first screening LDCT. J Thorac Oncol. 2021;16:S913\u20134.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"13008_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung Cancer. J Thorac Oncol. 2016;11(1):39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"13008_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1513\/AnnalsATS.202106-733OC","volume":"19","author":"SM Regis","year":"2022","unstructured":"Regis SM, Borondy-Kitts A, McKee AB, et al. Outcomes of positive and suspicious findings in clinical computed tomography lung Cancer screening and the road ahead. Ann Am Thorac Soc. 2022;19(8):1371\u20138. https:\/\/doi.org\/10.1513\/AnnalsATS.202106-733OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"13008_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S1470-2045(21)00590-8","volume":"23","author":"MC Tammem\u00e4gi","year":"2022","unstructured":"Tammem\u00e4gi MC, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International lung screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2022;23(1):138\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(21)00590-8.","journal-title":"Lancet Oncol"},{"issue":"3","key":"13008_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/1940-6207.CAPR-13-0206","volume":"7","author":"FE McRonald","year":"2014","unstructured":"McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK lung screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014;7(3):362\u201371. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0206.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"22","key":"13008_CR31","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1002\/cncr.28326","volume":"119","author":"PF Pinsky","year":"2013","unstructured":"Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National lung screening trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013;119(22):3976\u201383. https:\/\/doi.org\/10.1002\/cncr.28326.","journal-title":"Cancer"},{"key":"13008_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2022.12.011","volume":"176","author":"S Cressman","year":"2023","unstructured":"Cressman S, Weber MF, Ngo PJ, et al. Economic impact of using risk models for eligibility selection to the international lung screening trial. Lung Cancer. 2023;176:38\u201345. https:\/\/doi.org\/10.1016\/j.lungcan.2022.12.011.","journal-title":"Lung Cancer"},{"issue":"3","key":"13008_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7326\/M22-2216","volume":"176","author":"I Toumazis","year":"2023","unstructured":"Toumazis I, Cao P, de Nijs K, et al. Risk Model-Based lung Cancer screening: A Cost-Effectiveness analysis. Ann Intern Med. 2023;176(3):320\u201332. https:\/\/doi.org\/10.7326\/M22-2216.","journal-title":"Ann Intern Med"},{"issue":"12","key":"13008_CR34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","volume":"14","author":"R Luengo-Fernandez","year":"2013","unstructured":"Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165\u201374. 2045(13)70442-X.","journal-title":"Lancet Oncol"},{"issue":"1","key":"13008_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12885-019-5428-4","volume":"19","author":"R Wood","year":"2019","unstructured":"Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer. 2019;19(1):214. https:\/\/doi.org\/10.1186\/s12885-019-5428-4. Published 2019 Mar 8.","journal-title":"BMC Cancer"},{"issue":"5","key":"13008_CR36","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.21037\/tlcr-20-890","volume":"10","author":"JP van Meerbeeck","year":"2021","unstructured":"van Meerbeeck JP, Franck C. Lung cancer screening in europe: where are we in 2021? Transl Lung Cancer Res. 2021;10(5):2407\u201317. https:\/\/doi.org\/10.21037\/tlcr-20-890.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"13008_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1470-2045(15)00449-0","volume":"17","author":"S Vogler","year":"2016","unstructured":"Vogler S, Vitry A, Babar ZU. Cancer drugs in 16 European countries, australia, and new zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(15)00449-0.","journal-title":"Lancet Oncol"},{"issue":"3","key":"13008_CR38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1513\/AnnalsATS.202006-631RL","volume":"18","author":"M Triplette","year":"2021","unstructured":"Triplette M, Thayer JH, Kross EK, et al. The impact of smoking and screening results on adherence to Follow-Up in an academic multisite lung Cancer screening program. Ann Am Thorac Soc. 2021;18(3):545\u20137. https:\/\/doi.org\/10.1513\/AnnalsATS.202006-631RL.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"13008_CR39","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.21037\/tlcr-20-750","volume":"10","author":"M Rodr\u00edguez","year":"2021","unstructured":"Rodr\u00edguez M, Ajona D, Seijo LM, et al. Molecular biomarkers in early stage lung cancer. Transl Lung Cancer Res. 2021;10(2):1165\u201385. https:\/\/doi.org\/10.21037\/tlcr-20-750.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"13008_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12967-021-02849-8","volume":"19","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Zheng F, et al. Optimizing the timing of diagnostic testing after positive findings in lung cancer screening: a proof of concept radiomics study. J Transl Med. 2021;19(1):191. https:\/\/doi.org\/10.1186\/s12967-021-02849-8. Published 2021 May 4.","journal-title":"J Transl Med"},{"key":"13008_CR41","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/app.12031568","volume":"12","author":"G Torres","year":"2022","unstructured":"Torres G, Baeza S, Sanchez C, et al. An intelligent radiomic approach for lung cancer screening. Appl Sci (Basel). 2022;12:1568. https:\/\/doi.org\/10.3390\/app.12031568.","journal-title":"Appl Sci (Basel)"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13008-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:37:26Z","timestamp":1757317046000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-13008-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13008"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13008-w","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1001"}}